SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 10, 2004
HALSEY DRUG CO., INC.
616 N. North Court, Suite 120, Palatine, Illinois 60067
(847-705-7709)
I.R.S. Employer
Incorporated under the laws Commission File Number Identification Number
of State of New York 1-10113 11-0853640
Item 5. Other Events
On June 10, 2004, Halsey Drug Co., Inc. (the "Company") issued a press
release disclosing (a) the completion of a $14.0 million offering of the
Company's convertible debentures pursuant to the Debenture and Share Purchase
Agreement executed by the Company in February 2004, and (b) an amendment to the
Debenture and Share Purchase Agreement to (i) increase the principal amount of
debentures issuable thereunder from $14.0 million to $17.5 million and (ii)
extend the time to complete such additional financing from June 5, 2004 to
June 30, 2004.
A copy of the Company's press release is attached as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(b) Exhibits
Exhibit
Number Description
------ -----------
99.1 Press Release of Halsey Drug Co.,Inc. dated June 10, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
HALSEY DRUG CO., INC.
By: /s/ Peter A. Clemens
---------------------------
Peter A. Clemens
Senior Vice President &
Chief Financial Officer
Date: June 10, 2004
3
EXHIBIT INDEX
-------------
Exhibit
Number Description
------ -----------
99.1 Press Release dated June 10, 2004.
4